Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan

被引:269
作者
Takahashi, K [1 ]
Saito, K
Takahara, S
Okuyama, A
Tanabe, K
Toma, H
Uchida, K
Hasegawa, A
Yoshimura, N
Kamiryo, Y
机构
[1] Niigata Univ, Grad Sch Med & Dent Sci, Dept Regenerat & Transplant Med, Div Urol, Niigata, Japan
[2] Osaka Univ, Grad Sch Med, Dept Specif Organ Regulat Urol, Osaka, Japan
[3] Tokyo Womens Med Univ, Kidney Ctr, Dept Urol, Tokyo, Japan
[4] Nagoya Daini Red Cross Hosp, Dept Transplantat Surg, Nagoya, Aichi, Japan
[5] Toho Univ, Sch Med, Dept Nephrol, Tokyo, Japan
[6] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Surg & Regenerat Med, Kyoto, Japan
[7] Saiseikai Shimonoseki Gen Hosp, Dept Urol, Yamaguchi, Japan
关键词
ABO-incompatibility; accommodation; end-stage renal disease; immunosuppression; transplantation;
D O I
10.1111/j.1600-6143.2004.00464.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Owing to the severe shortage of cadaveric grafts in Japan, we have performed ABO-incompatible living donor kidney transplantation since 1989. This study assessed short- and long-term outcomes in 441 patients who received ABO-incompatible living donor kidney transplants between January 1989 and December 2001. We compared our results with historical data from 1055 recipients of living kidney transplantation. Overall patient survival rates 1, 3, 5, 7, and 9 years after ABO-incompatible transplantation were 93%, 89%, 87%, 85%, and 84%, respectively. Corresponding overall graft survival rates were 84%, 80%, 71%, 65%, and 59%. After ABO-incompatible transplantation, graft survival rates were significantly higher in patients 29 years or younger than in those 30 years or older and in patients who received anticoagulation therapy than in those who did not receive such therapy. There were no significant differences between A-incompatible and B-incompatible recipients with respect to clinical outcomes. The graft survival rate at 1 year in the historical controls was slightly but not significantly higher than that in our recipients of ABO-incompatible transplants. We conclude that long-term outcome in recipients of ABO-incompatible living kidneys is excellent. Transplantation of ABO-incompatible kidneys from living donors is a radical, but effective treatment for end-stage renal disease.
引用
收藏
页码:1089 / 1096
页数:8
相关论文
共 52 条
[21]   SPLENECTOMY IN HIGH-RISK PRIMARY RENAL-TRANSPLANT RECIPIENTS [J].
OKIYE, SE ;
ZINCKE, H ;
ENGEN, DE ;
STERIOFF, S ;
OFFORD, KP ;
FROHNERT, PP ;
JOHNSON, WJ .
AMERICAN JOURNAL OF SURGERY, 1983, 146 (05) :594-601
[22]   EFFECT OF SPLENECTOMY ON HUMAN RENAL-TRANSPLANTS [J].
OPELZ, G ;
TERASAKI, PI .
TRANSPLANTATION, 1973, 15 (06) :605-609
[23]  
OTA K, 1992, TRANSPLANT INT, V5, pS40
[24]   Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against anti body-mediated injury [J].
Park, WD ;
Grande, JP ;
Ninova, D ;
Nath, KA ;
Platt, JL ;
Gloor, JM ;
Stegall, MD .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (08) :952-960
[25]  
PETERS TG, 1983, ARCH SURG-CHICAGO, V118, P795
[26]   Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy [J].
Pierson, RN ;
Loyd, JE ;
Goodwin, A ;
Majors, D ;
Dummer, JS ;
Mohacsi, P ;
Wheeler, A ;
Bovin, N ;
Miller, GG ;
Olson, S ;
Johnson, J ;
Rieben, R ;
Azimzadeh, A .
TRANSPLANTATION, 2002, 74 (01) :79-84
[27]   Antibody-mediated rejection criteria - an addition to the Banff '97 Classification of Renal Allograft Rejection [J].
Racusen, LC ;
Colvin, RB ;
Solez, K ;
Mihatsch, MJ ;
Halloran, PF ;
Campbell, PM ;
Cecka, MJ ;
Cosyns, JP ;
Demetris, AJ ;
Fishbein, MC ;
Fogo, A ;
Furness, P ;
Gibson, IW ;
Glotz, D ;
Hayry, P ;
Hunsickern, LN ;
Kashgarian, M ;
Kerman, R ;
Magil, AJ ;
Montgomery, R ;
Morozumi, K ;
Nickeleit, V ;
Randhawa, P ;
Regele, H ;
Seron, D ;
Seshan, S ;
Sund, S ;
Trpkov, K .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :708-714
[28]  
REDBERG L, 2001, T MED, V11, P325
[29]  
ROWLEY DA, 1950, J IMMUNOL, V64, P289
[30]   Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor [J].
Ryo, R ;
Saigo, K ;
Hashimoto, M ;
Kohsaki, M ;
Yasufuku, M ;
Watanabe, N ;
Okada, M ;
Tadokoro, K ;
Juji, T .
VOX SANGUINIS, 1999, 76 (04) :241-246